Introduction
============

Osteoarthritis (OA) is a degenerative joint disease frequently affecting the knee and afflicting the constantly increasing elderly population.[@b1-cia-8-1289],[@b2-cia-8-1289] Knee OA symptoms include pain, stiffness, and functional limitation, leading to loss of autonomy and poor quality of life in patients affected by this disease.[@b3-cia-8-1289] Nowadays, various treatment options are available for the management of this condition. They include: nonsteroidal anti-inflammatory drugs (NSAIDs) for pain management;[@b4-cia-8-1289] bisphosphonates to decrease pain and improve functionality preserving the structural integrity of subchondral bone;[@b5-cia-8-1289] therapeutic exercise;[@b6-cia-8-1289] viscosupplementation with hyaluronic acid alone or in combination with bisphosphonates or NSAIDs to improve pain and functional activity[@b7-cia-8-1289]--[@b9-cia-8-1289] since hyaluronic acid improves articular cartilage degeneration and decreases osteophyte formation, as showed by experimental studies using OA models.[@b10-cia-8-1289],[@b11-cia-8-1289] These treatment modalities are effective in reducing pain and inflammation, but their long-term administration is associated with a high incidence of side effects or may not be applicable to the elderly.[@b12-cia-8-1289] Building upon these foundations, there is an urgent need for alternative therapies for this pathological condition. Pulsed electromagnetic field (PEMF) therapy has proved to be safe and has also shown promising therapeutic effectiveness on bone- and cartilage-related pathologies, including knee and cervical spine OA.[@b13-cia-8-1289]--[@b18-cia-8-1289]

Aim
---

The aim of this study was to investigate the clinical efficacy of a PEMF device for management of knee OA in elderly patients.

Materials and methods
=====================

Patients
--------

A total of 33 patients were screened, and 28 patients, aged between 60 and 83 (69.9 ± 1.5 \[mean ± Standard Error of the Mean {SEM}\]) and affected by bilateral knee OA, were enrolled in this study. All patients signed the informed consent. The protocol was planned and applied in agreement with the Declaration of Helsinki and was approved by the Institutional Review Board at the Poliambulatorio del Secondo Parere (Modena, Italy), where the procedure was performed.

Inclusion/exclusion criteria
----------------------------

The inclusion criteria for this study were a diagnosis of bilateral knee OA according to the Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association,[@b19-cia-8-1289] recurrent joint pain for at least a year prior to treatment, and daily pain in the knee ≥30 mm, as assessed by a 1--100 mm Visual Analog Scale (VAS). The exclusion criteria were: unilateral knee OA, intra-articular administration of drugs to the affected knees within 6 months before the study, systemic corticosteroid therapy or physiotherapy (iontophoresis with anti-inflammatory drugs, soft \[not heating\] laser, and ultrasound therapy) in the previous 6 weeks, and knee pain due to malignant, autoimmune and inflammatory pathologies or resulting from defective pathologies of the knee.

Therapeutic regimen
-------------------

PEMF therapy was performed using the Magnetofield device (F&B International, Parma, Italy). The applicators were held at the sides of the knee by a velcro band. The medical device combines low and high frequencies by means of 2 local devices in the shape of a hemisphere. The low-frequency field releases an intensity between 50 and 100 Gauss. The high-frequency field develops an intensity between 60 and 80 decibel relative to 1 volt (dBV)/meter (m). Low frequency takes the form of a square wave with frequency comprised between 6 and 100 Hz and duty cycle comprised between 30% and 70%. The high frequency also takes the form of a square wave, which is made up of a modulating and a carrier wave (continuous modulation). The modulating wave frequency varies between 100 and 5000 Hz, with duty cycle constant at 50%. The carrier-wave frequency varies between 20 and 30 MHz, with duty cycle at 50%.

In the present study, the patients underwent two consecutive therapeutic regimens: (1) 6÷100 Hz (low frequency) and 500÷2000 Hz (high frequency) for 15 minutes, and (2) 6÷100 Hz (low frequency) and 100÷5000 Hz (high frequency) for 15 minutes. A total of three 30-minute sessions per week for a period of 6 weeks were administered to each patient. The right leg was treated with PEMF therapy, while the left leg did not receive any treatment and was used as control ([Figure 1](#f1-cia-8-1289){ref-type="fig"}). An intravenous drip, containing ketoprofen (4 mL \[160 mg/mL\]; Dompè Farmaceutici, Milan, Italy), sodium clodronate (10 mL \[30 mg/mL\]; Abiogen Pharma, Pisa, Italy), glucosamine sulfate (1 mL \[1.5 mg/mL\]; Rottapharm, Monza, Italy), calcitonin (1 mL \[100 Ui/mL\]; Sandoz Industrial Products, Trento, Italy), and ascorbic acid (5 mL \[0.2 g/mL\]; Bayer, Milan, Italy), was administered while patients were receiving PEMF therapy.

Assessment of results
---------------------

VAS and the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) have been extensively used in clinical investigations to assess pain, stiffness, and physical function in patients affected by knee OA.[@b20-cia-8-1289]--[@b22-cia-8-1289] In our study, VAS (0--100 mm, 0 = no pain, 100 = maximum pain) and WOMAC (subscore 0--20, 0 = minimum pain, 20 = maximum pain) were used to measure knee-related pain at baseline and at 3 months post-PEMF therapy. Furthermore, WOMAC was also used to determine knee-related stiffness (subscore 0--8, 0 = minimum stiffness, 8 = maximum stiffness) and physical function (subscore 0--68, 0 = minimum physical function, 68 = maximum physical function).

Statistical analysis
--------------------

All data are represented as the means ± SEM and were analyzed using GraphPad Prism 5.04 (GraphPad Software Inc., San Diego, CA, USA). Changes in VAS and WOMAC scores were calculated for both knees as baseline minus post-treatment. An unpaired two-sample Student's *t*-test was used to compare change in knee-related VAS and WOMAC scores for PEMF-treated leg (mean ± SEM) vs control leg (mean ± SEM). *P* \< 0.05 was considered significant.

Results
=======

A total of 28 patients participated in the present study. At baseline, no significant difference was observed in mean VAS and WOMAC pain and mean WOMAC stiffness and physical function between left and right knee. VAS pain in the right knee changed from a baseline of 78.2 ± 1.2 to 28.4 ± 1.2 mm at 3 month follow-up. VAS pain in the control knee changed from a baseline of 78.2 ± 1.9 to 67.2 ± 1.7 mm at 3 month follow-up. In the right knee, WOMAC pain, stiffness, and physical function changed from baseline values of 15.6 ± 0.3, 6.3 ± 0.2, and 54.4 ± 1.8 to 7.1 ± 0.3, 2.8 ± 0.1, and 15.8 ± 0.9 at 3 month follow-up, respectively. In the control knee, WOMAC pain, stiffness, and physical function changed from baseline values of 15.3 ± 0.3, 6.3 ± 0.2, and 54.5 ± 1.8 to 12.9 ± 0.4, 4.7 ± 0.2, and 50.03 ± 1.8 at 3 month follow-up, respectively.

At 3 month follow-up, knee-related VAS pain significantly improved in PEMF-treated leg (49.8 ± 2.03) if compared with control leg (11 ± 1.1; *P* \< 0.001, [Figure 2](#f2-cia-8-1289){ref-type="fig"}). At 3 month follow-up, knee-related WOMAC pain, stiffness, and physical function significantly improved in PEMF-treated leg (8.5 ± 0.4, 3.5 ± 0.2 and 38.5 ± 2.08, respectively) if compared with control leg (2.6 ± 0.2, 1.6 ± 0.1 and 4.5 ± 0.5, respectively; *P* \< 0.001, [Figure 3](#f3-cia-8-1289){ref-type="fig"}). No adverse reactions to therapy were observed.

Discussion
==========

Experimental studies had previously shown that PEMF therapy produces an anabolic effect on the two key cell types in the skeletal system, ie, osteoblasts and chondrocytes[@b23-cia-8-1289]--[@b26-cia-8-1289] that are involved in experimental and clinical OA. Furthermore, PEMF therapy possesses healing properties at the cellular level.[@b27-cia-8-1289]--[@b31-cia-8-1289] In the present study we investigated the efficacy of PEMF therapy for management of knee OA-related pain, stiffness and physical function in elderly patients. We observed a significant improvement in all the above mentioned endpoints at the 3-month follow-up in the knee receiving PEMF therapy, if compared to the control knee without adverse events. Previous studies show contrasting results on the efficacy of PEMF therapy in the management of knee OA-related symptoms. Positive results, consistent with a significant improvement in activities of daily living, stiffness and pain following PEMF therapy, were reported in 83 patients affected by knee OA, if compared with control subjects at 6- and 12-week follow-up following a 6-week therapy.[@b32-cia-8-1289] This evidence was confirmed by another study involving 34 patients affected by early knee OA, who experienced a 50% decrease in VAS pain starting at day 1 and persisting up to day 42.[@b33-cia-8-1289] Findings from Fischer and coworkers showed positive results in 71 knee OA patients who underwent low-frequency PEMF therapy for 6 weeks.[@b34-cia-8-1289] Patients had an increase in mobility and walking distance test, with long-term analgesic and functional effects even at 4 weeks after the end of treatment.[@b34-cia-8-1289] A significant improvement in WOMAC score was also observed in 75 patients affected by knee OA, who received a 6-week PEMF therapy.[@b35-cia-8-1289]

Trock and colleagues also reported an improvement in pain and functional performance in patients affected by knee OA undergoing PEMF therapy for about 1 month, if compared to control group.[@b15-cia-8-1289] In opposition to the studies mentioned above, Ozgüçlü and coworkers performed a study involving 40 patients undergoing PEMF therapy for 2 weeks and found no differences between sham and treated group concerning WOMAC pain, stiffness, and physical function scores.[@b36-cia-8-1289] Ay and Evcik observed a significant improvement in pain in 55 patients affected by knee OA after hot pack/therapeutic ultrasound/PEMF therapy, but this improvement was also present in the sham group after five sessions per week for 2 weeks.[@b37-cia-8-1289] In our study, we observed a slight decrease in VA S and WOMAC pain, stiffness, and physical function in the control knee likely due to the intravenous drip. Therefore, a therapy combining PEMF therapy and an intravenous drip containing ketoprofen, sodium clodronate, glucosamine sulfate, calcitonin and ascorbic acid may be helpful to provide increased and accelerated relief from knee OA-related symptoms.

Conclusion
==========

PEMF therapy produces a significant benefit in terms of reduction in knee-related pain, stiffness, and physical function in elderly patients with knee OA. Further studies need to be designed to determine effectiveness of PEMF therapy in the long-term follow-up and clarify its mechanism.
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![Change in knee-related VAS pain for PEMF-treated leg vs control leg. Data are presented as the means ± SEM.\
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